文献速递脊柱关节炎

比美吉珠单抗对银屑病关节炎患者报告疾病影响的作用:两项3期研究1年结果

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于BE OPTIMAL、BE COMPLETE和BE VITAL研究,评估比美吉珠单抗160 mg每4周治疗银屑病关节炎患者1年患者报告疾病影响(PsAID-12)。共纳入1112例患者(比美吉珠单抗698例,安慰剂414例),比美吉珠单抗治疗第4周快速改善并持续至1年,PsAID-12总分较基线变化在随机接受比美吉珠单抗与第16周换用比美吉珠单抗的患者间相当。结论认为比美吉珠单抗在bDMARD初治和TNFi-IR患者中产生快速且持续的临床有意义改善。

要点

  • 比美吉珠单抗治疗第4周快速改善,持续至第16周并维持至1年。
  • 1年时PsAID-12总分变化:bDMARD初治组比美吉珠单抗-2.3 vs 安慰剂/比美吉珠单抗-2.2;TNFi-IR组-2.5 vs -2.2。
  • 第16周达到临床有意义改善(≥3分下降)的比例维持至1年:bDMARD初治49.0%,TNFi-IR 48.5%。

核心结论

  • 比美吉珠单抗治疗在bDMARD初治和TNFi-IR银屑病关节炎患者中,至1年产生快速且持续的临床有意义疾病影响改善。

研究设计与样本

  • 基于BE OPTIMAL(NCT03895203;bDMARD初治)、BE COMPLETE(NCT03896581;TNFi-IR)和BE VITAL(NCT04009499;开放标签扩展)研究的事后分析,评估比美吉珠单抗160 mg每4周治疗银屑病关节炎患者,共纳入1112例患者(比美吉珠单抗698例,安慰剂414例)。

主要发现

  • 比美吉珠单抗治疗第4周快速改善,持续至第16周并维持至1年。
  • 1年时PsAID-12总分较基线平均(SE)变化:bDMARD初治组比美吉珠单抗-2.3(0.1),安慰剂/比美吉珠单抗-2.2(0.1);TNFi-IR组比美吉珠单抗-2.5(0.1),安慰剂/比美吉珠单抗-2.2(0.2)。
  • 第16周达到临床有意义个体内改善(≥3分下降)的比例维持至1年:bDMARD初治组49.0%,TNFi-IR组48.5%;安慰剂/比美吉珠单抗组bDMARD初治44.4%,TNFi-IR 40.6%。
  • 各研究和组中,35.3%至47.8%的患者在1年时症状影响极小或无影响。
  • 所有单项领域(包括疼痛、疲劳和皮肤问题)至1年均观察到改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate 1-year bimekizumab efficacy in PsA from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire. METHODS: BE OPTIMAL (NCT03895203; biologic DMARD [bDMARD]-naïve), BE COMPLETE (NCT03896581; inadequate response/intolerance to TNF inhibitors [TNFi-IR]) and BE VITAL (NCT04009499; open-label extension) assessed bimekizumab 160 mg every 4 weeks in patients with PsA. Post hoc analyses of patient-reported disease impact, assessed by the PsAID-12 questionnaire, are reported to 1 year (collected to Week 40 in BE COMPLETE). RESULTS: Overall, 1,112 total patients were included (698 bimekizumab, 414 placebo). Rapid improvements observed with bimekizumab treatment at Week 4 continued to Week 16 and were sustained to 1 year. At 1 year, mean (SE) change from baseline in PsAID-12 total score was comparable between bimekizumab-randomized patients and patients who switched to bimekizumab at Week 16 (bDMARD-naïve bimekizumab -2.3 [0.1], placebo/bimekizumab -2.2 [0.1]; TNFi-IR bimekizumab -2.5 [0.1], placebo/bimekizumab -2.2 [0.2]). Proportions of bimekizumab-randomized patients achieving clinically meaningful within-patient improvement (≥3-point decrease from baseline) at Week 16 were sustained to 1 year (bDMARD-naïve 49.0%; TNFi-IR 48.5%) and were similar for placebo/bimekizumab patients (bDMARD-naïve 44.4%; TNFi-IR 40.6%). Across studies and arms, 35.3% to 47.8% of patients had minimal or no symptom impact at 1 year. Improvements were observed to 1 year across all single-item domains, including pain, fatigue and skin problems. CONCLUSION: Bimekizumab treatment resulted in rapid and sustained clinically meaningful improvements in disease impact up to 1 year in bDMARD-naïve and TNFi-IR patients with PsA. TRIAL REGISTRATION: BE OPTIMAL: NCT03895203; BE COMPLETE: NCT03896581; BE VITAL: NCT04009499 (ClinicalTrials.gov).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gossec L, Orbai AM, de Wit M, et al. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. Rheumatology (Oxford). 2024. PMID: 38754125. doi:10.1093/rheumatology/keae277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。